Novartis to Acquire Avidity Biosciences
Novartis, an innovative medicines company, has agreed to acquire Avidity Biosciences, a leader in RNA therapeutics, to strengthen its late-stage neuroscience pipeline.
Novartis aims to reimagine medicine, improving and extending people's lives, and empowering patients, healthcare professionals, and societies in the face of serious disease. The company's medicines reach 296 million people worldwide.
Resources and Commitments
- Information for patients and caregivers: clinical trial recruiting, managed access programs, funding opportunities, and side effects reporting.
- Resources for healthcare professionals: clinical trial recruiting, grant funding, congresses, and country-level information.
- Commitments to environmental, social, and governance: providing access to innovative medicines, protecting the environment, and upholding high ethical standards.
Discover how Novartis turns breakthrough science into transformative, high-value treatments.
Learn more about Novartis' impact on the world through the Novartis in Society Integrated Report.
Author's summary: Novartis acquires Avidity Biosciences to boost neuroscience pipeline.
More News
- Opinion: Mamdani’s proposed Department of Community Safety would be a win for New Yorkers
- Jacksonville-based tech innovator ParkerVision stifled by Chinese interference, judicial abuse
- Myles Garrett Passes T.J. Watt on Career Sacks List
- Defenders of the Amazon targeted in Ecuador
- Garbage menace and irresponsible behaviour - Star of Mysore
- Somber Start, Triumphant Finish: Furusato Claims Maiden Victory Amid Difficult Day in Sepang
- Recycling innovator maps out quick, connected translation path
- Shreya Sen-Handley | Ditch That Smartphone, Get Out, Get A W/Life
- Trinity Students Share Their Dublin Marathon Experiences
- ‘Chainsaw Man’ Whips Past $100M WW; ‘One Battle After Another’ Keeps Raging – International Box Office